Genetically modified non-human animal with human or chimeric CD28
The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.
1. A genetically-modified, non-human mammal whose genome comprises a nucleic acid sequence encoding a chimeric CD28 at an endogenous CD28 gene locus, wherein the chimeric CD28 comprises a humanized CD28 extracellular region and an endogenous CD28 cytoplasmic region, and the nucleic acid sequence encoding the chimeric CD28 is operably linked to an endogenous CD28 promoter, wherein the mammal is homozygous with respect to the nucleic acid sequence encoding the chimeric CD28 and expresses the chimeric CD28.
2. The mammal of claim 1 , wherein the mammal is a rodent.
3. The mammal of claim 1 , wherein the mammal is a mouse.
4. The mammal of claim 1 , wherein the genome of the mammal comprises a nucleic acid sequence encoding a portion of an extracellular region of a human CD28 in place of a nucleic acid sequence encoding a corresponding portion of an extracellular region of an endogenous CD28.
5. The mammal of claim 1 , wherein the chimeric CD28 comprises a humanized CD28 extracellular region, an endogenous CD28 transmembrane region, and an endogenous CD28 cytoplasmic region.
6. The mammal of claim 1 , wherein the mammal further comprises a sequence encoding an additional human or chimeric protein.
7. The mammal of claim 6 , wherein the additional human or chimeric protein is programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte Activating 3 (LAG-3), B And T Lymphocyte Associated (BTLA), Programmed Cell Death 1 Ligand 1 (PD-L1), CD27, CD40, CD47, CD137, CD154, T-Cell Immunoreceptor With Ig And ITIM Domains (TIGIT), T-cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), Glucocorticoid-Induced TNFR-Related Protein (GITR), Signal regulatory protein α (SIRPα), or TNF Receptor Superfamily Member 4 (OX40).
8. A method of determining effectiveness of an anti-CD28 antibody for treating cancer, comprising:
administering the anti-CD28 antibody to the mammal of claim 1 , wherein the mammal has a cancer; and
determining inhibitory effects of the anti-CD28 antibody to the cancer.
9. The method of claim 8 , wherein the anti-CD28 antibody is an anti-human CD28 antibody.
10. The mammal of claim 3 , wherein the chimeric CD28 comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 33.
11. The mammal of claim 3 , wherein the chimeric CD28 comprises SEQ ID NO: 33.
12. A genetically-modified, non-human mammal whose genome comprises a chimeric CD28 gene at an endogenous CD28 gene locus, wherein the chimeric CD28 gene comprises a nucleic acid sequence encoding a portion of an extracellular region of a human CD28 in place of a nucleic acid sequence encoding a corresponding portion of an extracellular region of an endogenous CD28, wherein the chimeric CD28 gene is operably linked to an endogenous CD28 promoter, wherein the mammal expresses a chimeric CD28, and the mammal does not express endogenous CD28, wherein the portion of the extracellular region of the human CD28 comprises at least 50 amino acid residues of the extracellular region of the human CD28.
13. The mammal of claim 12 , wherein the portion of the extracellular region of the human CD28 comprises at least 100 amino acid residues of the extracellular region of the human CD28.
14. A genetically-modified rodent whose genome comprises a nucleic acid sequence encoding a humanized CD28 at an endogenous CD28 gene locus, wherein the humanized CD28 comprises a humanized CD28 extracellular region, an endogenous CD28 transmembrane region, and an endogenous CD28 cytoplasmic region, and the nucleic acid sequence encoding the humanized CD28 is operably linked to an endogenous CD28 promoter, wherein the rodent is homozygous with respect to the nucleic acid sequence encoding the humanized CD28 and expresses the humanized CD28.
15. The rodent of claim 14 , wherein the rodent is a mouse.